I posted the "LOL" before you edited your own post.
I think it's an excellent deal on all fronts. The economic terms are close to what I would have expected if IDIX had already run a phase-2 trial showing superiority to Sustiva.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”